JPM vs PDT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
PDT exhibits a stable but stagnant financial profile, anchored by a Piotroski F-Score of 4/9 and a Graham Number of $20.92 that suggests significant defensive undervaluation. While the fund offers an attractive 7.49% dividend yield and trades at a low P/E of 9.50 relative to the sector average of 35.00, these strengths are countered by a severe -40.5% collapse in earnings growth. The technical trend is currently bearish (0/100), and the discrepancy between the Graham Number and the growth-based intrinsic value ($9.73) indicates a conflict between asset value and earning power.
Compare Another Pair
Related Comparisons
JPM vs PDT: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and John Hancock Premium Dividend Fund (PDT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.